Daiwa Securities Group
UBX

Daiwa Securities Group’s Unity Biotechnology UBX Stock Holding History

Daiwa Securities Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12
Closed – – 1446
2021
Q3 		$0 Hold
12
– – ﹤0.01% 1341
2021
Q2 		$1K Hold
12
– – ﹤0.01% 1217
2021
Q1 		$1K Hold
12
– – ﹤0.01% 1228
2020
Q4 		$1K Sell
12
-15
-56% -$723 ﹤0.01% 1207
2020
Q3 		$1K Hold
27
– – ﹤0.01% 1169
2020
Q2 		$2K Hold
27
– – ﹤0.01% 1166
2020
Q1 		$2K Hold
27
– – ﹤0.01% 1166
2019
Q4 		$2K Hold
27
– – ﹤0.01% 1171
2019
Q3 		$2K Hold
27
– – ﹤0.01% 1136
2019
Q2 		$3K Hold
27
– – ﹤0.01% 1135
2019
Q1 		$2K Sell
27
-13
-33% -$1.47K ﹤0.01% 1141
2018
Q4 		$7K Buy
+40
New +$5.31K ﹤0.01% 1031

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Daiwa Securities Group's UBX Position: Q4 2021 in Review

Daiwa Securities Group sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 12 shares.

Daiwa Securities Group first reported a position in UBX in Q4 2018 and held it in 12 quarters. The position peaked at $7K in Q4 2018. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Daiwa Securities Group reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Daiwa Securities Group sold 12 Unity Biotechnology shares in Q4 2021.
  • Daiwa Securities Group first reported a position in Unity Biotechnology in Q4 2018 and held it in 12 quarters.
  • Daiwa Securities Group's Unity Biotechnology position peaked at $7K in Q4 2018.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.